5.8173
1.73%
0.0273
Kodiak Sciences Inc stock is traded at $5.8173, with a volume of 20,601.
It is up +1.73% in the last 24 hours and up +60.49% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
See More
Previous Close:
$5.79
Open:
$5.79
24h Volume:
20,601
Relative Volume:
0.08
Market Cap:
$302.53M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-1.0206
EPS:
-5.7
Net Cash Flow:
$-158.88M
1W Performance:
+11.13%
1M Performance:
+60.49%
6M Performance:
+83.49%
1Y Performance:
+161.78%
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
KOD | 5.8869 | 302.53M | 0 | -197.68M | -158.88M | -5.70 |
VRTX | 447.65 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.27 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.49 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
Dec-11-23 | Resumed | Goldman | Sell |
Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
Jul-27-23 | Downgrade | UBS | Buy → Neutral |
Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
Nov-15-22 | Initiated | CapitalOne | Overweight |
Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-11-22 | Initiated | Goldman | Buy |
Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
Mar-12-21 | Initiated | Evercore ISI | Outperform |
Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Dec-17-20 | Initiated | Berenberg | Buy |
Dec-16-20 | Initiated | UBS | Buy |
Dec-11-20 | Initiated | Citigroup | Neutral |
Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
Mar-03-20 | Initiated | Goldman | Buy |
Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-06-20 | Initiated | SunTrust | Buy |
Jan-08-20 | Initiated | ROTH Capital | Buy |
Jan-03-20 | Initiated | Jefferies | Buy |
Dec-24-19 | Initiated | JP Morgan | Overweight |
Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
Oct-29-18 | Initiated | Barclays | Overweight |
Oct-29-18 | Initiated | BofA/Merrill | Buy |
Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
GSA Capital Partners LLP Makes New Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - MarketBeat
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade) - Seeking Alpha
Kodiak Sciences (NASDAQ:KOD) Given New $4.00 Price Target at Barclays - MarketBeat
Kodiak Sciences Inc (KOD) Quarterly 10-Q Report - Quartzy
Kodiak Sciences: Drug Shows 3x Longer Half-Life, Reports $43.9M Q3 Loss | KOD Stock News - StockTitan
Diabetic Retinopathy Clinical Trials 2024: FDA Approvals, - openPR
Kodiak Sciences to Present at Two Major Healthcare Investor Conferences | KOD Stock News - StockTitan
Report Finds Big Disparities in Americans' Well-Being by Region - 69News WFMZ-TV
Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death - 69News WFMZ-TV
Diabetes & Kidney Trouble Can Bring Heart Disease Decades Earlier - 69News WFMZ-TV
Hourglass-Shaped Stent Might Ease Tough-to-Treat Angina - 69News WFMZ-TV
Bystanders More Readily Perform CPR If 911 Operator Instructs - 69News WFMZ-TV
How ADHD May Influence a Child's Weight - 69News WFMZ-TV
Have an Implanted Defibrillator? Triple-Digit Heatwaves Could Pose Danger - 69News WFMZ-TV
Obesity-Linked Heart Deaths Nearly Tripled in U.S. Over Past Two Decades - 69News WFMZ-TV
Empowering Growth: Diabetic Macular Edema Market 2024 - openPR
Age-Related Macular Degeneration Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight - Barchart
Bow-legged girl 14 cm taller after life-changing surgery - 69News WFMZ-TV
Kodiak Sciences (KOD) Price Target Increased by 25.00% to 5.10 - MSN
Zacks Research Raises Earnings Estimates for Kodiak Sciences - MarketBeat
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Sanctuary Advisors LLC Purchases New Holdings in Denny’s Co. (NASDAQ:DENN) - Defense World
3 US Penny Stocks With Market Caps Under $500M To Consider - Simply Wall St
Financial Comparison: Kodiak Sciences (NASDAQ:KOD) & Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update - MarketBeat
Pacific Seafood to take over Trident Seafoods’ Kodiak operations - just-food.com
Campaigning begins for Japan's parliamentary election - 69News WFMZ-TV
KODKodiak Sciences Inc Latest Stock News & Market Updates - StockTitan
Kodiak Sciences to Present at Innovate Retina 2024 - cnhinews.com
Retinal Vein Occlusion Market Size is Set for Rapid Growth as - openPR
How early is too early to prep for Thanksgiving? - 69News WFMZ-TV
Expect employers to get more picky about who you see for care - 69News WFMZ-TV
Documents show OpenAI's long journey from nonprofit to $157B valued company - 69News WFMZ-TV
Could Certain Genes Help You Slim Down? - 69News WFMZ-TV
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks - Yahoo Finance
Having COVID-19 doubles risk of heart attack or stroke: study - 69News WFMZ-TV
VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
Innovator U.S. Equity Accelerated 9 Buffer ETF – January (BATS:XBJA) Shares Sold by Cetera Investment Advisers - Defense World
Vanguard Personalized Indexing Management LLC Buys Shares of 17,896 Redfin Co. (NASDAQ:RDFN) - Defense World
Natural Grocers by Vitamin Cottage (NYSE:NGVC) Stock Price Up 4.8% - Defense World
Susquehanna Portfolio Strategies LLC Has $330,000 Stake in SandRidge Energy, Inc. (NYSE:SD) - Defense World
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Xponance Inc. Sells 12,667 Shares of Mattel, Inc. (NASDAQ:MAT) - Defense World
Inozyme Pharma (NASDAQ:INZY) Earns Outperform Rating from Wedbush - Defense World
Retinal Disorder Treatment Market Share Report, Industry Share and Trends Analysis By 2033 - WhaTech
Data Storage (NASDAQ:DTST) Stock Quotes, Forecast and News Summary - Benzinga
Evergreen Capital Management LLC Raises Position in Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NYSE:HASI) - Defense World
Retinal Biologics Market Advancements Highlighted by Size, Share Analysis And Forecast Report 2024 To 2033 - WhaTech
Goldman Sachs maintains sell rating on Kodiak Sciences stock By Investing.com - Investing.com South Africa
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):